Abstract:STING (Stimulator of Interferon Genes, also known as ERIS, MITA and MPYS) is an important adaptor protein in innate immunity.It plays a key role in cytosolic DNA mediated IFN production.STING is the direct sensor of cyclic dinucleotides(CDN) in cytosol, including c-di-GMP from pathogen and cGAMP synthesized by cGAS after DNA stimulating.After binding to and activated by CDNs, STING recruits and activates TBK1 and IRF3 by its C terminal tail.IRF3 is phosphorylated and then dimerize to enter nucleus, resulting in type I interferon (IFN) production.5,6-dimethylxanthenone-4-acetic acid (DMXAA) and 10-carboxymethyl-9-acridanone (CMA) were identified as antitumor/antiviral compounds which acted very well in mouse model but failed in human clinical trial.Further research showed that DMXAA and CMA bind to and activate mouse STING, but not human STING.To further investigate the mechanism of ligands' species selectivity, we studied on human STING(hSTING), rat STING(rSTING) and mouse STING(mSTING) by functional and structural analysis.We found that human and rat STINGs display more similar signaling profiles toward DMXAA and CMA than that of human and mouse STINGs, suggesting that rat is more suitable for preclinical testing of STING-targeted drugs.Previous research showed that a single point mutation in hSTING S162A renders hSTING sensitive to DMXAA.Through molecular dynamics simulations, we revealed how this single mutation alter the DMXAA-STING interaction.Compared to mutated systems, structural correlations in the interaction of STING with DMXAA are stronger, and the correlations are cross-protomers in the dimeric protein.Analyses on correlation coefficients lead to the identification of two key interactions that mediate the strong cross-protomer correlation in the DMXAA-STING interaction network: DMXAA-267T-162S* and 238R-260E*.These two interactions are partially and totally interrupted by the S162A and E260I mutations, respectively.Moreover, a smaller number of water molecules are displaced upon DMXAA binding to STING than that on binding to its mutants, leading to a larger entropic penalty for the former.Considering the sensitivity of STING and two of its mutants to DMXAA, a strong structural correlation appears to discourage DMXAA-STING binding.Such an observation suggests that DMXAA derivatives, which are deprived of hydrogen-bond interaction with both 162S* and 267T, are potential agonists of human STING.Taken together, our findings suggest better animal model for STING-targeted drugs and shed light on optimization of hSTING agonist.

A clinically-relevant STING agonist restrains human TH17 cell inflammatory profile

STING is an intrinsic checkpoint inhibitor that restrains the TH17 cell pathogenic program

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.

Structural Insights into a Shared Mechanism of Human STING Activation by a Potent Agonist and an Autoimmune Disease-Associated Mutation.

Intrinsic STING Switches off Pathogenetic Programs of Th1 Cells to Inhibit Colitis

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of TH1 and TH9 cells

Targeting STING in dendritic cells alleviates psoriatic inflammation by suppressing IL-17A production

STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity

Suppression of systemic autoimmunity by the innate immune adaptor STING

Targeting STING oligomerization with small-molecule inhibitors

Antitumor/antiviral Drugs Target on STING

DNA sensing via STING regulates autoimmunity and tumor immunity. (IRM5P.648)

PROTAC based STING degrader attenuates acute colitis by inhibiting macrophage M1 polarization and intestinal epithelial cells pyroptosis mediated by STING-NLRP3 axis

STING activation in alveolar macrophages and group 2 innate lymphoid cells suppresses IL-33–driven type 2 immunopathology

Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist

STING Agonists/Antagonists: Their Potential as Therapeutics and Future Developments

Prolonged activation of innate immune pathways by a polyvalent STING agonist

Abstract 667: Inhibition of protein-protein interaction between STING and TRIM29 is a new approach to enhance anti-tumor immune response

Stimulator of Interferon Genes Agonists attenuate type I diabetes progression in NOD mice.